ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis
A Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-501 Oral Suspension Compared to Placebo in Adult Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis
In the register
The register attaches this trial to ATI-501 (Aclaris Therapeutics), currently at “Discontinued” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- Phase 2
- Sponsor
- Aclaris Therapeutics, Inc.
- Participants (registry)
- 87
- Start
- June 2018
- Primary completion
- June 2019
- Study completion
- June 2019
- Last registry update
- September 2020
- Countries
- United States
Conditions studied: Alopecia
Interventions: ATI-501 400mg BID (Low dose), Active comparator: Low dose, ATI-501 600mg BID (Mid dose), Comparator : Mid dose, ATI-501 800mg BID (High dose), Comparator: high dose - oral administration, Placebo
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.